公开(公告)号：US09851358B2

公开(公告)日：2017-12-26

申请号：US15109942

申请日：2015-01-07

申请人： INSERM (Institut National de la Sante et de la Recherche Medicale ,  Universite Paul Sabatier Toulouse III ,  Centre Hospitalier Universitaire de Toulouse ,  Universite de Bourgogne ,  Universite de Rennes 1 ,  Universite des Antilles et de la Guyane ,  Ecole des Hautes Etudes en Sante Publique (EHESP)

发明人： Patrick Legembre ,  Bruno Segui ,  Thierry Levade ,  Olivier Micheau

IPC分类号： G01N33/574 ,  A61K31/164 ,  A61K9/127

CPC分类号： G01N33/57484 ,  A61K9/127 ,  A61K31/164 ,  G01N33/57415 ,  G01N2800/52

摘要： The present invention relates to methods and pharmaceutical compositions for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells). In particular, the present invention relates to a method for preventing or reducing metastatic dissemination (i.e. reducing motility of cancer cells) in a subject suffering from a cancer comprising the steps consisting of i) determining the expression level of at least one biomarker selected from the group consisting of soluble CD95L and EMT promoting factors in a sample obtained from the subject, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) administering the subject with a therapeutically effective amount of C16-ceramide or derivatives such as C16-sphingomyelin and C16-glycosphingolipids when the expression level determined at step i) is higher than the predetermined reference value.

公开(公告)号：US11078277B2

公开(公告)日：2021-08-03

申请号：US16074555

申请日：2017-02-01

申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  UNIVERSITE PAUL SABATIER TOULOUSE III ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE

发明人： Thierry Levade ,  Bruno Segui ,  Florie Bertrand ,  Julia Rochotte ,  Anne Montfort ,  Nathalie Andrieu-Abadie ,  Celine Colacios Viatge ,  Nicolas Meyer

IPC分类号： A61K48/00 ,  A61P35/00 ,  C12N15/86 ,  C07K16/28 ,  A61K38/46 ,  A61K31/713 ,  A61K39/00 ,  A61K9/127 ,  C12N9/16 ,  G01N33/569

摘要： The present invention relates to methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer. In particular, the present invention relates to a method of enhancing the CD8+ T cell-dependent immune response in a subject suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent capable of increasing intra-tumoral ceramide content.

公开(公告)号：US10918737B2

公开(公告)日：2021-02-16

申请号：US16073141

申请日：2017-01-27

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PAUL SABATIER TOULOUSE III ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE

发明人： Thierry Levade ,  Bruno Segui ,  Nicolas Meyer ,  Céline Colacios Viatgé ,  Nathalie Andrieu-Abadie ,  Florie Bertrand

IPC分类号： A61P35/00 ,  A61K47/68 ,  C07K16/24 ,  C07K16/28 ,  A61K39/395 ,  A61K39/00 ,  A61K45/06

摘要： The present invention relates to methods and pharmaceutical composition for the treatment of cancer. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen for cancer, the method comprising: administering a pharmaceutically effective amount of a TNFα blocking agent to a subject in combination with the immune checkpoint inhibitor.

公开(公告)号：US10144772B2

公开(公告)日：2018-12-04

申请号：US15310158

申请日：2015-05-12

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE ,  INSTITUT CLAUDIUS REGAUD ,  UNIVERSITÉ PAULS SABATIER TOULOUSE III

发明人： Bruno Segui ,  Nathalie Andrieu-Abadie ,  Thierry Levade ,  Celine Colacios Viatge ,  Philippe Rochaix ,  Florie Bertrand ,  Herve Benoist ,  Julia Rochotte

IPC分类号： A61K38/17 ,  A61K39/00 ,  C07K16/24 ,  C07K16/28 ,  C07K16/30 ,  C07K14/715 ,  G01N33/574

摘要： The present invention relates to a TNFα blocking agent for use in the treatment and prevention of melanoma in a subject in whom melanoma cells express MHCI and in whom stroma cells exhibit TNF expression.

公开(公告)号：US10822415B2

公开(公告)日：2020-11-03

申请号：US16073080

申请日：2017-01-27

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  Université Toulouse III—Paul Sabatier ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE

发明人： Thierry Levade ,  Nicolas Meyer ,  Céline Colacios Viatgé ,  Caroline Imbert ,  Nathalie Andrieu-Abadie ,  Bruno Segui

IPC分类号： A61K39/00 ,  C07K16/28 ,  A61K31/133 ,  A61K31/137 ,  A61K31/40 ,  A61K31/415 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/4535 ,  A61K45/06 ,  A61K39/395 ,  G01N33/569 ,  A61P35/00 ,  G01N33/574

摘要： The present invention relates to methods for enhancing the potency of the immune checkpoint inhibitors. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen, the method comprising administering a pharmaceutically effective amount of a SK1 inhibitor to a subject in combination with the immune checkpoint inhibitor.